Esperion Historical Financial Ratios
| ESPR Stock | USD 0.99 0.03 2.94% |
Esperion Therapeutics is recently reporting on over 107 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 84.78 or Invested Capital of 0.0 will help investors to properly organize and evaluate Esperion Therapeutics financial condition quickly.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Esperion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. About Esperion Financial Ratios Analysis
Esperion TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Esperion Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Esperion financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Esperion Therapeutics history.
Esperion Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Esperion Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Esperion Therapeutics sales, a figure that is much harder to manipulate than other Esperion Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Most ratios from Esperion Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Esperion Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Esperion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.At this time, Esperion Therapeutics' Receivables Turnover is relatively stable compared to the past year.
| 2022 | 2023 | 2024 | 2025 (projected) | Payables Turnover | 1.17 | 1.36 | 1.33 | 0.79 | Days Of Inventory On Hand | 476.45 | 553.6 | 502.75 | 477.61 |
Esperion Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Esperion Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Esperion Therapeutics fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 3.14 | 1.84 | 5.48 | 2.65 | 1.24 | 1.18 | |
| Ptb Ratio | (0.85) | (0.13) | (0.31) | (0.68) | (1.06) | (1.01) | |
| Book Value Per Share | (3.5) | (6.81) | (4.88) | (4.41) | (2.08) | (1.97) | |
| Free Cash Flow Yield | (0.14) | (1.83) | (0.42) | (0.44) | (0.0582) | (0.0611) | |
| Operating Cash Flow Per Share | (2.6) | (3.1) | (9.13) | (2.63) | (1.31) | (0.13) | |
| Stock Based Compensation To Revenue | 0.12 | 0.31 | 0.2 | 0.1 | 0.0361 | 0.0343 | |
| Capex To Depreciation | 0.57 | 2.99 | 24.44 | 5.03 | 4.53 | 4.76 | |
| Pb Ratio | (0.85) | (0.13) | (0.31) | (0.68) | (1.06) | (1.01) | |
| Ev To Sales | 2.61 | 2.5 | 7.29 | 6.59 | 1.7 | 1.78 | |
| Free Cash Flow Per Share | (5.56) | (2.63) | (3.59) | (9.13) | (1.31) | (0.13) | |
| Roic | (0.53) | (0.84) | (1.22) | (1.81) | 0.36 | 0.38 | |
| Net Income Per Share | (6.05) | (11.03) | (4.33) | (2.03) | (0.28) | (0.29) | |
| Payables Turnover | 0.046 | 0.81 | 1.17 | 1.36 | 1.33 | 0.79 | |
| Sales General And Administrative To Revenue | 0.44 | 0.79 | 2.18 | 1.3 | 1.17 | 0.66 | |
| Research And Ddevelopement To Revenue | 0.65 | 1.35 | 1.58 | 0.74 | 0.14 | 0.13 | |
| Cash Per Share | 11.1 | 8.97 | 2.51 | 0.8 | 0.77 | 0.73 | |
| Pocfratio | (8.39) | (0.55) | (2.37) | (2.28) | (17.41) | (18.28) | |
| Interest Coverage | (5.35) | (4.89) | (3.16) | (2.64) | 0.92 | 0.96 | |
| Capex To Operating Cash Flow | (0.001016) | (0.0135) | (0.16) | (0.0134) | (0.0121) | (0.0127) | |
| Pfcf Ratio | (7.25) | (0.55) | (2.37) | (2.28) | (17.18) | (18.04) | |
| Days Payables Outstanding | 7.9K | 450.8 | 311.85 | 267.57 | 274.81 | 261.07 | |
| Income Quality | 0.72 | 0.59 | 0.98 | 0.75 | 0.65 | 0.46 | |
| Roe | 0.2 | 0.29 | 0.21 | 0.46 | 0.13 | 0.14 | |
| Ev To Operating Cash Flow | (6.98) | (0.74) | (3.15) | (5.66) | (23.87) | (22.68) | |
| Pe Ratio | (4.3) | (0.45) | (1.44) | (1.47) | (7.96) | (8.36) | |
| Return On Tangible Assets | (0.47) | (0.84) | (1.16) | (1.02) | (0.15) | (0.16) | |
| Ev To Free Cash Flow | (6.04) | (0.74) | (3.15) | (5.66) | (23.56) | (22.38) | |
| Earnings Yield | (0.0675) | (0.23) | (2.21) | (0.7) | (0.68) | (0.13) | |
| Intangibles To Total Assets | 1.59E-4 | 1.47E-4 | 2.26E-4 | 2.72E-4 | 1.63E-4 | 1.55E-4 | |
| Net Debt To E B I T D A | 0.99 | (0.23) | (0.77) | (3.06) | 20.19 | 21.2 | |
| Current Ratio | 3.68 | 4.48 | 2.67 | 1.29 | 1.37 | 1.3 | |
| Tangible Book Value Per Share | (3.5) | (6.82) | (4.88) | (4.41) | (2.08) | (1.97) | |
| Shareholders Equity Per Share | (30.53) | (38.28) | (20.18) | (4.41) | (2.08) | (2.18) | |
| Debt To Equity | (0.22) | (0.24) | (0.19) | (1.19) | (0.77) | (0.73) | |
| Capex Per Share | 0.005644 | 0.0352 | 0.49 | 0.001694 | 0.001948 | 0.00185 |
Pair Trading with Esperion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Esperion Stock
The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.
The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.